|Year : 2018 | Volume
| Issue : 1 | Page : 94-96
Bleb needling with subconjunctival ologen insertion using IOL cartridge
Tanuj Dada1, Dewang Angmo1, Shibal Bhartiya2, Karthikeya Ramananda1
1 Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All Institute of Medical Sciences, New Delhi, India
2 Glaucoma Specialist, Fortis Memorial Research Institute, Gurgaon, Haryana, India
|Date of Web Publication||5-Mar-2018|
Dr. Rajendra Prasad Centre for Ophthalmic Sciences, Room No. S-1, First Floor, All India Institute of Medical Sciences, New Delhi - 110 029
Source of Support: None, Conflict of Interest: None
| Abstract|| |
We describe a novel technique to bleb needling by injecting subconjunctival ologen through an intraocular lens (IOL) delivery system to modulate wound healing in a failing filter. Bleb needling with 26G needle was performed, followed by subconjunctival injection of a biodegradable collagen implant using an IOL delivery system with cartridge in two eyes with a failing filter and high intraocular pressure (IOP). Postoperatively, the bleb was diffusely elevated, and the IOP was maintained between 10 and 14 mmHg at 6 weeks, 3 and 6 months follow-up. Therefore, bleb needling augmented with a biodegradable collagen implant inserted through an IOL injector system is a useful option in the management of failing filter posttrabeculectomy.
Keywords: 5-Fluorouracil, bleb needling, failed filtering surgery, intraocular lens delivery system, ologen
|How to cite this article:|
Dada T, Angmo D, Bhartiya S, Ramananda K. Bleb needling with subconjunctival ologen insertion using IOL cartridge. Oman J Ophthalmol 2018;11:94-6
|How to cite this URL:|
Dada T, Angmo D, Bhartiya S, Ramananda K. Bleb needling with subconjunctival ologen insertion using IOL cartridge. Oman J Ophthalmol [serial online] 2018 [cited 2020 May 25];11:94-6. Available from: http://www.ojoonline.org/text.asp?2018/11/1/94/226336
| Introduction|| |
Trabeculectomy remains the surgery of choice in patients with advanced glaucoma, but failure of filtration may be caused by subconjunctival and episcleral fibrosis. The success rate of bleb needling with 5-fluorouracil (5FU) injection varies between 75% and 94%., However, risk factors for failure of needle revision include preneedling intraocular pressure (IOP) >30 mmHg, aphakia or pseudophakia, a fornix-based conjunctival flap during surgery, with previous surgery involving a conjunctival incision; as was present in our case., We, therefore, added a biodegradable collagen implant to the standard procedure of needling to modulate wound healing and augment the success of this procedure.
| Case Reports|| |
A 54-year-old male with the diagnosis of OD Aphakia with corneal decompensation, spheroidal degeneration, fibrous downgrowth and secondary glaucoma, posttrabeculectomy, and OS absolute eye; presented with IOP of 32 mmHg. The patient had undergone trabeculectomy with 0.02% mitomycin C (MMC), 2 months back and a mildly elevated, vascularized, encysted bleb was noted [Figure 1]a. Best-corrected visual acuity in the right eye was only light perception with accurate projection of rays and no light perception in the left eye.
|Figure 1: (a) Preoperative photograph showing a flat vascularized bleb. (b) Postoperative photograph showing a diffusely raised bleb|
Click here to view
A 61-year-old male with the diagnosis of OU pseudophakia with OS secondary glaucoma with twice operated trabeculectomy; presented with IOP of 28 mmHg. The patient had undergone trabeculectomy with 0.02% MMC, 6 weeks back and a relatively flat, extensively vascularized bleb was noted.
| Materials and Methods|| |
In both the cases, needling with 5 FU, 5 mg/0.1 ml was performed with additional use of a biodegradable collagen implant to maintain the subconjunctival space and modulate wound healing in the postoperative period.
The ologen implant (Biodegradable Collagen Matrix Implant, Aeon Astron Europe, The Netherlands) is a porous implant comprising >90% Type I atelocollagen and <10% lyophilized glycosaminoglycan with a pore size of 10–300 μm. We used a cylindrical implant of 6 mm diameter and 2 mm in height (Model No. 830601).
After anesthetizing, the eye with topical proparacaine 0.5% drops, a wire speculum was inserted, and a 30G needle loaded on 2 ml syringe was advanced into the bleb and swept in a side to side motion within Tenon's fascia, making multiple perforations within the bleb wall while still preserving the overlying conjunctiva. The ologen implant (6 mm × 2 mm) was loaded into the IOL cartridge using a McPherson's forceps [Figure 2]. Thereafter, a small (1.5 mm) conjunctival opening was made with Westcott scissors, 10 mm from the limbus and blunt dissection performed. The ologen implant was then injected through this opening, using a Monarch© III IOL Delivery System in a D cartridge (Alcon, Fort Worth, Texas, USA) [Figure 3]a and [Figure 3]b. After injection, the implant was gently massaged 2 mm away from the limbus to maintain a slightly posterior bleb. A watertight closure of the conjunctiva was done with a single 8-0 polyglactin horizontal mattress suture. Thereafter, 0.1 ml of 5 FU (5 mg/0.1 ml) was injected posterior to the bleb with a 30G needle, loaded on a tuberculin syringe.
|Figure 2: Intraoperative photograph showing the loading of ologen implant (6 mm × 2 mm) into the D cartridge using a McPherson's forceps|
Click here to view
|Figure 3: (a) Intraoperative photograph showing ologen (6 mm × 2 mm) loaded into the D cartridge. (b) Intraoperative photograph showing injection of ologen through a Monarch© III intraocular lens Delivery System in a D cartridge through a small conjunctival opening|
Click here to view
| Results|| |
Postoperatively, the bleb was diffusely elevated [Figure 1]b, and the IOP was 8 mmHg at 1 week, 12–14 mmHg at 6 weeks, 3 and 6 months follow-up in the first case (on no medications). In the second case, IOP was 12 mmHg at 1 week, 14 mmHg at 6 weeks and 3 months, and 16 mmHg at 6-month follow-up (on timolol + brimonidine eye drops BD). Anterior segment optical coherence tomography of the bleb at 3-month follow-up showed a raised bleb with multiple small hyporeflective spaces, suggestive of a filtering bleb along with subconjunctival ologen in situ [Figure 4].
|Figure 4: (a) Preoperative anterior segment optical coherence tomography of the bleb showing a flat bleb with no hyporeflective spaces, suggestive of a failing bleb. (b) Postoperative anterior segment optical coherence tomography at 3-month follow-up showing a raised bleb with hyporeflective spaces, suggestive of a filtering bleb with subconjunctival ologen in situ (red asterisk)|
Click here to view
The principle of ologen (Biodegradable Collagen Matrix Implant) is to induce the fibroblast to randomize within its porous matrix, which leads to the formation of a loose connective tissue. It also maintains the subconjunctival space preventing adhesion and scarring while supporting and maintaining the size of the bleb even after partial degradation.
Dada et al. have previously reported encouraging short-term results with the use of subconjunctival ologen implant with anti-scarring agents for trabeculectomy. The use of subconjunctival ologen implant after needling may be a useful adjunct in eyes with a high risk of failure of trabeculectomy. In addition, the use of intraocular lens (IOL) injector system for subconjunctival ologen insertion, usually employed in microincision cataract surgery, helps in minimizing tissue injury by reducing the size of the incision and taking it away from the area of the bleb, thereby reducing scarring at the site of the scleral flap.
| Conclusion|| |
We report a new application of ologen implant with needling for a failing filter posttrabeculectomy using a small incision technique. The use of subconjunctival ologen with bleb needling has not been previously reported in literature and we encourage clinical trials in the future, using this technique for improving the management of failing blebs – a common clinical challenge after trabeculectomy.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Skuta GL, Parrish RK 2nd
. Wound healing in glaucoma filtering surgery. Surv Ophthalmol 1987;32:149-70.
Ewing RH, Stamper RL. Needle revision with and without 5-fluorouracil for the treatment of failed filtering blebs. Am J Ophthalmol 1990;110:254-9.
Hodge W, Saheb N, Balazsi G, Kasner O. Treatment of encapsulated blebs with 30-gauge needling and injection of low-dose 5-fluorouracil. Can J Ophthalmol 1992;27:233-6.
Hawkins AS, Flanagan JK, Brown SV. Predictors for success of needle revision of failing filtration blebs. Ophthalmology 2002;109:781-5.
Shin DH, Juzych MS, Khatana AK, Swendris RP, Parrow KA. Needling revision of failed filtering blebs with adjunctive 5-fluorouracil. Ophthalmic Surg 1993;24:242-8.
Zelefsky JR, Hsu WC, Ritch R. Biodegradable collagen matrix implant for trabeculectomy. Expert Rev Ophthalmol 2008;3:613-7.
Dada T, Kusumesh R, Bali SJ, Sharma S, Sobti A, Arora V, et al.
Trabeculectomy with combined use of subconjunctival collagen implant and low-dose mitomycin C. J Glaucoma 2013;22:659-62.
[Figure 1], [Figure 2], [Figure 3], [Figure 4]